H.C. Wainwright Reiterates Buy Rating on Krystal Biotech (KRYS)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $240.00 price target on Krystal Biotech (NASDAQ: KRYS).

The analyst commented: "As we approach 2Q25 results, likely in August, we believe there are a couple of underlying themes to the Vyjuvex results that continued to provide volatility to the shares; however, we continue to be pleased with the launch trajectory with this first-in-class therapy. There is a keen focus on the quarterly financial results for Vyjuvex, and to date, the company has been quite transparent about the various components of the launch, that we discuss within. We reiterate our Buy rating and $240 PT."

For an analyst ratings summary and ratings history on Krystal Biotech click here. For more ratings news on Krystal Biotech click here.

Shares of Krystal Biotech closed at $138.88 yesterday.

You May Also Be Interested In

• IBM (IBM) PT Raised to $350 at Oppenheimer
• Goldman Sachs on Conviction List Buy rated Wells Fargo (WFC): 'We expect a modestly positive investor response'
• Barclays on JPMorgan (JPM): 'expenses and tax rate were higher than anticipated'